Announcement PDF Neurizon Receives Addifional R&D Tax Incenfive Rebate 11 December 2024 – Melbourne, Australia: Neurizon Therapeufics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerafive diseases, is pleased to announce that the Company has received an addifional rebate of $650,707 under the Federal Government’s Research and Development (R&D) Tax Incenfive scheme in respect of eligible overseas expenditure incurred in the 2023/24 financial year, following submission of an Advance Overseas Finding Applicafion to AusIndustry. This follows the inifial R&D Tax Incenfive Rebate received amounfing to $887,129 for eligible Australian or local expenditure incurred in the 2023/24 financial year, as announced on 9 October 2024. Dr. Michael Thurn, Managing Director and Chief Execufive Officer of Neurizon, commented: “We confinue to appreciate the support that the Federal Government provides for our programs. This addifional R&D Tax Incenfive Rebate strengthens Neurizon’s cash posifion further and will be primarily applied toward preparafions for the adapfive Phase 2/3 HEALEY ALS Plafform Trial, GMP grade MPL manufacturing, preclinical models for other neurodegenerafive diseases, regulatory filings and general working capital.” -ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeufics Limited. For further informafion, please contact: Dr. Michael Thurn Managing Director and Chief Execufive Officer Neurizon Therapeufics Limited enquiries@neurizon.com +61 (3) 9692 7222 Catherine Strong Sodali & Co catherine.strong@sodali.com +61 (0)406 759 268 About Neurizon Therapeufics Limited Neurizon Therapeufics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerafive diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effecfive ALS treatments for pafients, while exploring NUZ-001’s potenfial for broader neurodegenerafive applicafions. Through internafional collaborafions and rigorous clinical programs, Neurizon is dedicated to creafing new horizons for pafients and families impacted by complex neural disorders. Neurizon Investor Hub We encourage you to ufilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This plafform offers an opportunity to submit quesfions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit hftps://investorhub.neurizon.com Neurizon Therapeufics Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205 Tel: +61 3 9692 7222, www.neurizon.com 1